ALNY
TYPE Stocks
GROUP Stocks
BASE ALNY
SECOND US Dollar
<% (signals.list.current.rate).substr(0,7) %>
<% (signals.list.current.absolute).substr(0,9) %> (<% signals.list.current.percentage|toFixed:2 %>%)
MARKETS TREND
OPEN
<% (signals.list.current.openrate).substr(0,9) %>
HIGH
<% (signals.list.current.high).substr(0,9) %>
LOW
<% (signals.list.current.low).substr(0,9) %>
ALNY Signals
DON'T WANT TO MISS ANY SIGNAL? GO PREMIUM
ACCESS ALL FX, COMMODITIES & CRYPTO SIGNALS. GO PREMIUM
<% signal.pair %> (<% signal.rate %>) <% signal.action %>
<% signal.status %>
<% signal.analyst %><% signal.analyst %>
Long Term
Entry Price
Stop Loss
Take Profit
PREMIUM ONLY
<% signal.stopLoss %> N/A
PREMIUM ONLY
<% signal.takeProfit %> N/A
PREMIUM ONLY
<% signal.analyst %><% signal.analyst %>
<% signal.comment %>
Description
<% signal.description %>
LATEST ANALYSIS
<% item.time_ago %> Ago
<% item.title %>
<% item.deltaTime %>

ALNY Signals & Technical Analysis

Last Updated: <% indicators.interval.updated|date:'MMM d, y h:mm:ss a' %>
Market Trend
Strong Sell
Sell
Neutral
Buy
Strong Buy
Loading Market Trend ...

Market Sentiment

BUY: <% indicators.sentiment.buy.length %> SELL: <% indicators.sentiment.sell.length %> NEUTRAL: <% indicators.sentiment.neutral.length %>
Strong Sell
Sell
Neutral
Buy
Strong Buy

Trend Indicators

NAME
VALUE
ACTION
Bollinger Bands
UPPER: <% indicators.data[indicators.interval.active].bbands.value.upper %>
MIDDLE: <% indicators.data[indicators.interval.active].bbands.value.middle %>
LOWER: <% indicators.data[indicators.interval.active].bbands.value.lower %>
Sell
Buy
Parabolic SAR
<% indicators.data[indicators.interval.active].sar.value %>
Sell
Buy
Standard Deviation
<% indicators.data[indicators.interval.active].stddev.value %>
High Volatility
Low Volatility

Oscillators

NAME
VALUE
ACTION
RSI(14)
<% indicators.data[indicators.interval.active].rsi.value %>
Sell
Buy
MACD(12,26)
<% indicators.data[indicators.interval.active].macd.value %>
Buy
Sell
Neutral
ATR
<% indicators.data[indicators.interval.active].atr.value %>
High Volatility
Low Volatility
STOCH(9,6)
<% indicators.data[indicators.interval.active].stochastics.value %>
Buy
Sell
ADX
<% indicators.data[indicators.interval.active].adx.value %>
High Volatility
Low Volatility

Moving Averages

PERIOD
SIMPLE
EXPONENTIAL
MA5
<% indicators.data[indicators.interval.active].sma5.value %> Buy Sell
<% indicators.data[indicators.interval.active].ema5.value %> Buy Sell
MA10
<% indicators.data[indicators.interval.active].sma10.value %> Buy Sell
<% indicators.data[indicators.interval.active].ema10.value %> Buy Sell
MA20
<% indicators.data[indicators.interval.active].sma20.value %> Buy Sell
<% indicators.data[indicators.interval.active].ema20.value %> Buy Sell
MA50
<% indicators.data[indicators.interval.active].sma50.value %> Buy Sell
<% indicators.data[indicators.interval.active].ema50.value %> Buy Sell
MA100
<% indicators.data[indicators.interval.active].sma100.value %> Buy Sell
<% indicators.data[indicators.interval.active].ema100.value %> Buy Sell

Pivot

PIVOT
CLASSIC
FIBONACCI
CAMARILLA
WOODIE
S3
<% indicators.data[indicators.interval.active].pp.data.result.classic.s3 %>
<% indicators.data[indicators.interval.active].pp.data.result.fibonacci.s3 %>
<% indicators.data[indicators.interval.active].pp.data.result.camarilla.s3 %>
<% indicators.data[indicators.interval.active].pp.data.result.woodie.s3 %>
S2
<% indicators.data[indicators.interval.active].pp.data.result.classic.s2 %>
<% indicators.data[indicators.interval.active].pp.data.result.fibonacci.s2 %>
<% indicators.data[indicators.interval.active].pp.data.result.camarilla.s2 %>
<% indicators.data[indicators.interval.active].pp.data.result.woodie.s2 %>
S1
<% indicators.data[indicators.interval.active].pp.data.result.classic.s1 %>
<% indicators.data[indicators.interval.active].pp.data.result.fibonacci.s1 %>
<% indicators.data[indicators.interval.active].pp.data.result.camarilla.s1 %>
<% indicators.data[indicators.interval.active].pp.data.result.woodie.s1 %>
PP
<% indicators.data[indicators.interval.active].pp.data.result.classic.pp %>
<% indicators.data[indicators.interval.active].pp.data.result.fibonacci.pp %>
<% indicators.data[indicators.interval.active].pp.data.result.camarilla.pp %>
<% indicators.data[indicators.interval.active].pp.data.result.woodie.pp %>
R1
<% indicators.data[indicators.interval.active].pp.data.result.classic.r1 %>
<% indicators.data[indicators.interval.active].pp.data.result.fibonacci.r1 %>
<% indicators.data[indicators.interval.active].pp.data.result.camarilla.r1 %>
<% indicators.data[indicators.interval.active].pp.data.result.woodie.r1 %>
R2
<% indicators.data[indicators.interval.active].pp.data.result.classic.r2 %>
<% indicators.data[indicators.interval.active].pp.data.result.fibonacci.r2 %>
<% indicators.data[indicators.interval.active].pp.data.result.camarilla.r2 %>
<% indicators.data[indicators.interval.active].pp.data.result.woodie.r2 %>
R3
<% indicators.data[indicators.interval.active].pp.data.result.classic.r3 %>
<% indicators.data[indicators.interval.active].pp.data.result.fibonacci.r3 %>
<% indicators.data[indicators.interval.active].pp.data.result.camarilla.r3 %>
<% indicators.data[indicators.interval.active].pp.data.result.woodie.r3 %>

About (ALNY) Alnylam Pharmaceuticals Inc.

Company Background

Alnylam Pharmaceuticals Inc. (Symbol: ALNY) is a pioneering biotechnology firm dedicated to transforming the treatment landscape for genetically-defined diseases. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam specializes in RNA interference (RNAi) technology, which enables the silencing of disease-causing genes at the RNA level. This innovative approach has positioned the company as a leader in developing therapies for rare and prevalent diseases associated with genetic mutations. With a commitment to scientific excellence and patient-centric solutions, Alnylam has become synonymous with groundbreaking advancements in the field of genetic medicine.

Market Position

Alnylam Pharmaceuticals holds a prominent position in the biopharmaceutical industry, particularly within the RNAi therapeutics market. With a robust pipeline of investigational and commercial products, the company has successfully launched several therapies, including ONPATTRO® (patisiran), which was the first-ever RNAi therapy approved for the treatment of hereditary transthyretin-mediated amyloidosis. This significant milestone not only underscores Alnylam's innovative capabilities but also highlights its dedication to addressing unmet medical needs. The company continues to expand its product offerings and explore new indications, reinforcing its status as a frontrunner in biotechnology.

Key Financial Highlights

Alnylam has demonstrated strong financial performance, supported by its innovative product portfolio and strategic partnerships. As of October 2023, the company reported significant revenue growth driven by the sales of its RNAi therapeutics. Alnylam's financial stability is further enhanced by collaborations with major pharmaceutical companies, which provide both funding and shared expertise. With a strong balance sheet and a growing market presence, Alnylam is well-positioned for future growth, focusing on expanding its pipeline and advancing new therapies through clinical trials. The company remains committed to exploring additional applications of its RNAi technology, thereby solidifying its leadership in the biotechnology sector.

Related Stocks

REGN logo
REGN
Regeneron Pharmaceuticals, Inc.
0
Industry Biotechnology
Exchange NASDAQ
JAZZ logo
JAZZ
Jazz Pharmaceuticals plc
0
Industry Biotechnology
Exchange NASDAQ
BMRN logo
BMRN
Biomarin Pharmaceutical Inc.
0
Industry Biotechnology
Exchange NASDAQ

HFM

Doo Prime

XM

Best Forex Brokers